Amarillo, Texas, September 6, 2017 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), has identified certain goals for its future business development, and wishes to share this information with both its shareholders, and the general public.  ABI recognizes that it needs to create new products and get them to market, monetize and commercialize its intellectual property, leverage core technology, and develop research capabilities to become an integrated healthcare enterprise of global distinction.  Additionally, ABI must transform itself from the historically narrow focus in biotechnology to a wide variety of development opportunities in several industry sectors.  By doing so, we can create multiple revenue streams through the implementation of programs (including but not limited to in-licensing) of novel medical, healthcare, and scientific products and processes.  For this strategy to be successful, we have to transform ABI from the traditional single-business unit into three modern, diversified, self-contained business operations: Pharmaceutical, Medical, and Consumer Products.

Read more: Amarillo Biosciences, Inc. Announces Investor Update

Amarillo, Texas, October 6, 2016 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that eight claims of its latest patent application, which apply the use of low-dose oral interferon to the reversal of Thrombocytopenia, have been allowed by the U.S. Patent & Trademark Office.  The patent is expected to issue before year end, 2016. ABI has full rights to exploit this patent in the U.S., Africa, India, Thailand, Malaysia, Australia, New Zealand, Indonesia, the Philippines, and certain other smaller markets.

Read more: Amarillo Biosciences, Inc. Receives Approval of Patent Claims – Treatment of Thrombocytopenia...

Amarillo, Texas, May 18, 2015 – Amarillo Biosciences, Inc. (ABI) (OTCBB and OTCQB:  AMAR) today summarized its new operating plan following the Company’s emergence from Chapter 11 Bankruptcy.  ABI disclosed that it had arisen from bankruptcy January 23, 2015, when the Final Decree closing the case had been signed by Judge Robert L. Jones of the United States Bankruptcy Court for the Northern District of Texas in Case No. 13-20393-RJL-11.

Read more: Amarillo Biosciences, Inc. Summarizes New Plan of Operation

Press Release

Amarillo, Texas, February 2,  2015 – Amarillo Biosciences, Inc. (ABI) (OTCBB and OTCQB:  AMAR) today announced that the Company has completely reorganized and emerged from the voluntary Chapter 11 Bankruptcy declared fifteen months ago.  The Order and Final Decree closing the case was signed by Judge Robert L. Jones of the Northern District of Texas, on January 23, 2015. 

Read more: Amarillo Biosciences, Inc. Reorganizes, Exits Bankruptcy, and Opens a New Chapter in the...

Copyright © 2018 Amarillo Biosciences. All Rights Reserved.
Built and hosted by Dark Roast Hosting